Ingenuity Systems Releases IPA™ 5.0 Software with Biomarker and Molecular Toxicology Capabilities

Ingenuity Systems has introduced Ingenuity Pathways Analysis 5.0, to offer specific functions for identifying biomarker candidates and characterizing molecular toxicity in a biological context.

IPA-Biomarker™ and IPA-Tox™, within the IPA application can enable researchers to mechanistically connect biomarkers to pathways of disease and drug response, and elucidate toxic effects not revealed by traditional methods.

In addition to these capabilities, IPA 5.0 contains an addition of new expert- extracted content from the scientific literature, including new knowledge about diseases, exogenous and endogenous chemicals, and drugs and clinical candidates.

"There is a substantive need for researchers to understand and examine their data in a biological framework," commented Walter Darbonne, Associate Scientist, Pharmacodynamic Biomarkers, Oncology at Genentech.

"As many of us know, most companies have invested a large number of resources in acquiring technologies that generate vast quantities of data but researchers are still unclear on how to translate discoveries made with those technologies into safe and effective drugs.” Dardonne continued.

He further said, “With IPA 5.0, we were able to quickly and easily identify molecular biomarkers in our dataset, connect them to mechanisms of disease or drug response, and then check where those proteins have been detected, for example in blood, urine, or the sentinel tissue blood. This is a huge advancement."

Ingenuity Pathways Analysis 5.0 is a software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research.

The system supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, identification of biomarkers, predictive toxicology, and pharmacogenomics.